On Wednesday, Revive Therapeutics Ltd., a tiny Toronto-based company that trades on the OTCQB as RVVTF, revealed that it secured FDA orphan drug designation for cannabidiol (CBD) to prevent hepatic ischemia and reperfusion injury resulting from solid organ transplantation. Under license from South Carolina Research Foundation, a unit of the University of South Carolina, Revive also is investigating REV-200, described as a cannabinoid CB1/CB2 receptor modulator, for the potential treatment of liver diseases such as autoimmune hepatitis and nonalcoholic steatohepatitis, or NASH. But the company, which markets a hemp-based CBD chewing gum branded Relicann, is primarily looking to partner the asset for development. A coveted FDA regulatory designation helps to set it apart.